MAPK1 and amyotrophic lateral sclerosis: Also, seeing the involvement of this cascade in amyotrophic lateral sclerosis (ALS), the use of ERK blockers like selumetinib and cobemetinib, which have otherwise been implicated in neurological disorders, has also been suggested in this neurodegenerative disorder (Albert-Gascó et al. 2020).